Skip to content

Robin Shane Readnour, Director at AN2 Therapeutics, sold ANTX on Aug 17, 2026

Data as of Oct 16

▼ SELL$100K16,696 shares at $6.01Robin Shane Readnour DirectorANTX AN2 Therapeutics, Inc.
Watch ANTX
Traded
Aug 17, 2026
Disclosed
Aug 19, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Robin Shane Readnour, Director at AN2 Therapeutics, sold ANTX on Aug 17, 2026TRADEDDISCLOSED
ANTXSimilar stocks (XLV — its sector index fund), rebased to ANTX's price on the disclosure day
ANTX since disclosure
−43.3%
after the sale
Similar stocks (XLV) since disclosure
+0.6%
XLV — its sector index fund

Change in closing price from Aug 19, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLRobin Shane Readnour DirectorANTX AN2 Therapeutics, Inc.$112Kdisclosed Aug 19 · filed 2 days after the trade

See every trade on ANTX →